NEUROCRINE BIOSCIENCES INC

Nasdaq: NBIX·San Diego, California·

Price
$165.31
Base IV
$220.32

Valuation snapshot

Below base case

At $165.31, the price sits between our bear case ($101.34) and base case ($220.32).

Values per share, from an .

No growth
…
Loading earnings power
Base case
$220.32
above today's price · range $101.34–$379.61
Price vs base case
25% below
$165.31 against $220.32
Base casevalued by DCF
Price vs base
Priceclose 11‑16

Whisker on the base case runs bear $101.34 to bull $379.61. Values per share.

Price against each value

Bear case
$101.34
Price 63% above
No growth
…
—
Base case
$220.32
Price 25% below
Researched byClaude Opus 5.5
Valuation Nov 13, 2026 · Price as of Nov 16, 2026How we got here

What does Neurocrine Biosciences do?

Neurocrine Biosciences develops and sells pharmaceutical treatments for patients with neurological, psychiatric, and endocrine disorders, including tardive dyskinesia and congenital adrenal hyperplasia.

It brought in $3.7B of sales in the 12 months to Sep 2026.

Led by Kyle W. Gano, Ph.D., Chief Executive Officer since 2024. Kyle W. Gano, Ph.D. — Neurocrine Biosciences

Industry
Healthcare
Based in
San Diego, California
Trades on
Nasdaq as NBIX

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 19¢ was left as profit after every cost, interest and tax. The biggest cost is sales, marketing and admin, 39¢ of every dollar.

  • Research and development33¢
  • Sales, marketing and admin39¢
  • Everything else it takes to operate4¢
  • Tax6¢
  • Left as profit19¢
  • Interest and other income came back in+1¢
Totals of the four quarters to Sep 2026, from the company's own filings. The split by product is from the latest fiscal year.

Who pays Neurocrine Biosciences, and for what?

Neurocrine Biosciences is a biopharmaceutical company that discovers, develops, and commercializes treatments for neurological, psychiatric, endocrine, and immunological disorders. It makes money primarily by selling proprietary prescription medications through specialty pharmacy and distributor networks.

Its customers include select specialty pharmacy providers, wholesale distributors, and specialty distributors.

  • INGREZZA

    88%

    An FDA-approved medicine for tardive dyskinesia and chorea associated with Huntington's disease.

  • CRENESSITY

    11%

    A first-in-class FDA-approved treatment for classic congenital adrenal hyperplasia.

  • Other Product Sales

    1%

    Other commercial product sales across the portfolio.

  • Collaboration Revenues

    1%

    Royalties earned on partner net sales of elagolix (AbbVie) and valbenazine (Tanabe Pharma Corporation).

Share of the latest fiscal year's sales, as the company reports it.

Where its work physically happens, beyond headquarters:

  • Soleno Redwood City Office — Redwood City, United States. Former Soleno headquarters (about 18,026 sq ft leased through August 2029, plus about 17,779 sq ft of expansion space) that came with the May 2026 acquisition and was the base of the VYKAT XR business, which had $190 million of 2025 revenue, though Neurocrine's filings reviewed do not confirm its current use.
See them on the globe

Neurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025

How is the business doing?

Sales grew from $1B in 2020 to $2.9B in 2025, about 22% a year.

Running the business leaves about 24¢ of each sales dollar as operating profit, up from 16¢ in 2020.

After paying for its upkeep and new investment, it had $1B of cash to spare in the 12 months to Sep 2026.

Sales$2.9B
20122025
Operating margin22%
20122025
Free cash flow$748.7M
20122025
Each bar is one fiscal year (2012–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

The company exists to discover, develop, and deliver life-changing medicines that relieve suffering for patients with serious and under-addressed disorders.

“To relieve suffering for people with great needs, but few options.”

Neurocrine Biosciences About Us

Who is responsible for the plan?

Roles checked November 13, 2026.

What management says it is working on now:

INGREZZA Net Product Sales, Full-Year 2026
$2,825 million to $2,875 million
Neurocrine Biosciences Reports Second Quarter 2026 Financial Results
Phase 1 Clinical Entries, Each year
At least 4 new programs
Neurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025
Phase 2 Clinical Entries, Each year
At least 2 new programs
Neurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025
New Medicine Launches, Every two years on average
Approximately 1 new medicine
Neurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is picking up. In Q3 2026 it sold 41% more than a year earlier. The year before, quarters averaged 34%.

Its operating margin is about where it was a year ago, 30¢ per sales dollar.

Since Oct 2026 the share price has risen 13%, from $146.38 to $165.31.

Bull $379.61Base $220.32Bear $101.34Oct 30Nov 16 · $165.31
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start October 30, 2026.

Recently

  • November 2, 2026

    VYKAT XR net product sales, full quarter changed to $107.0M

    NBIX Q3 2026 8-K
  • November 2, 2026

    Ingrezza net product sales, quarterly changed to $801.0M

    NBIX Q3 2026 8-K
  • November 2, 2026

    Crenessity net product sales, quarterly changed to $211.0M

    NBIX Q3 2026 8-K

Coming up

Our own estimate moved too: the base case went from $196.96 to $220.32 a share between our last two valuations. The biggest reason: VYKAT XR net product sales, full quarter moved from an unreported prior value to $107.0M, as reported in NBIX Q3 2026 8-K.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. High Product Concentration in INGREZZA

    The company relies heavily on INGREZZA for the vast majority of its total revenues, meaning any decline in demand or pricing would severely harm operations.

    From the company's own filingsWould hit how fast sales growNeurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025

  2. Reimbursement and Healthcare Pricing Pressures

    Government reforms like the Inflation Reduction Act, Medicare Part D redesigns, and private payor formulary restrictions could lower drug reimbursement and margins.

    From the company's own filingsWould hit how much of each sale it keepsNeurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025

  3. Commercial and Clinical Competition

    Competitors market rival treatments such as AUSTEDO and COBENFY, and newer therapeutics or generic equivalents could erode market share.

    From the company's own filingsWould hit how fast sales growNeurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025

  4. Clinical Trial and Development Failures

    Drug development carries substantial uncertainty, and product candidates may fail to show sufficient safety or efficacy in clinical trials.

    From the company's own filingsWould hit how much it has to reinvestNeurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025

  5. Reliance on Third-Party Contract Manufacturers

    The company owns no manufacturing facilities and relies entirely on external third parties for active pharmaceutical ingredients and product supply.

    From the company's own filingsWould hit how much of each sale it keepsNeurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025

  6. Government Investigation Risks

    The company received a civil investigative demand from the Department of Justice regarding INGREZZA marketing practices, which could bring penalties or restrictions.

    From the company's own filingsWould hit how much of each sale it keepsNeurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025

  7. Q3 included about a $20M Ingrezza benefit from customer order timing, which is expected to reverse in Q4.

    From our researchWould hit how fast sales growMarketBeat Q3 call highlights

  8. Austedo's 38% Medicare price cut from 2027 may pressure Ingrezza's pricing and formulary position.

    From our researchWould hit how fast sales growInvesting.com on Austedo MFP

Is it a good business?

From 2018 to 2025 it earned between 8% and 19% on the capital invested in it, a median of 13%. Its cost of capital in the latest valuation is 7.5%; returns were above it in every one of the 8 years.

From 2012 to 2025 it earned between -38% and 36% on its shareholders' equity, a median of 8%.

Over 10 years its operating margin ranged from $17.02 to 24¢ per sales dollar, a median of 11¢. Gross margin ran from 98¢ to 99¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on invested capital18%
20122025

Cost of capital 7.5%

Return on equity15%
20122025
Return on invested capital is operating profit after tax (at the median effective rate, 26%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

The number of shares grew 44% from 2012 to 2020, so each share owns a smaller slice of the business.

It holds $641.5M more in cash than it owes.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $165.31. Our put its value between $101.34 and $379.61, with $220.32 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $101.34

This scenario assumes Neurocrine's run of roughly 20-40% yearly sales growth cools quickly: its main drug Ingrezza levels off under Medicare price pressure, newer drugs grow more slowly than hoped, and profits stay near today's level.

Base case, $220.32

This scenario assumes Neurocrine keeps growing strongly next year as its newer drugs build on its main drug, then slows to steadier growth, with profits edging up from recent levels.

Bull case, $379.61

This scenario assumes Neurocrine's recent growth of about 40% a year carries into next year, its newer drugs become major products, and its research pipeline delivers new medicines, letting profits grow faster than sales.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects less than we do.Margin of safety: 25%

For Neurocrine Biosciences to be worth today's $165.31, sales would need to grow about 4.8% a year. We assume 11.6%. Over the last 5 years, sales grew 28.2% a year.

−10%0%+10%+20%+30%+40%Price needs 4.8%We assume 11.6%Past 5 yrs 28.2%

Or, if sales grow 11.6% as we assume, the price works with a profit margin of 24.5% (we assume 33.0%).

Keep in mind: a low price can mean investors see a risk that isn't in the filings yet. Check the Full research tab for what could go wrong.

Do you think sales can grow 4.8% a year?

Try your own numbers

We're not very sure of this range: it scores 44 out of 100 on our checks. The weakest point is historical stability.

Test the assumptions

Our base value of $220.32 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average11.6%

    Next year 25.0%, then about 8%

  • Operating margin33.0%
  • Long-term growth rate3.0%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$220.32 33.3%

Build